In preparation for rising cases of COVID-19, the United States Departments of Health and Human Services (HHS) and Defense (DoD) have purchased an additional 650,000 doses of Eli Lilly and Company’s investigational monoclonal antibody therapeutic, bamlanivimab. This puts the total number of treatment courses at 950,000 purchased, with the current 300,000 doses in the process of delivery. Additional doses should be delivered over the course of this month and January, with the treatments being shipped on to state and territorial health departments through a proportional system based on confirmed COVID-19 cases, then finally to specific healthcare facilities.

 

Read more…

The post HHS, DoD buy up 650,000 more doses of Eli Lilly’s COVID-19 antibody therapeutic appeared first on Healthier Environment Living Program.